Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP trimmed its position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 3.0% in the fourth quarter, HoldingsChannel reports. The firm owned 1,665,113 shares of the medical instruments supplier’s stock after selling 50,766 shares during the period. Dimensional Fund Advisors LP’s holdings in Harvard Bioscience were worth $3,513,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HBIO. Intech Investment Management LLC acquired a new position in Harvard Bioscience during the 4th quarter valued at about $35,000. Sei Investments Co. acquired a new stake in shares of Harvard Bioscience in the 4th quarter worth approximately $47,000. JPMorgan Chase & Co. lifted its stake in shares of Harvard Bioscience by 63.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after acquiring an additional 11,397 shares during the period. Barclays PLC lifted its stake in shares of Harvard Bioscience by 304.4% in the 3rd quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 44,150 shares during the period. Finally, Gamco Investors INC. ET AL acquired a new stake in shares of Harvard Bioscience in the 4th quarter worth approximately $200,000. 80.87% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

HBIO has been the subject of a number of research analyst reports. KeyCorp reaffirmed a “sector weight” rating on shares of Harvard Bioscience in a research note on Wednesday, April 9th. StockNews.com initiated coverage on shares of Harvard Bioscience in a research note on Wednesday. They issued a “hold” rating for the company. Finally, Benchmark reduced their price target on shares of Harvard Bioscience from $4.50 to $3.00 and set a “speculative buy” rating for the company in a research note on Tuesday.

Harvard Bioscience Stock Up 5.3%

HBIO stock opened at $0.37 on Wednesday. Harvard Bioscience, Inc. has a 12 month low of $0.29 and a 12 month high of $3.60. The firm has a market cap of $16.39 million, a PE ratio of -1.12 and a beta of 1.44. The firm has a 50 day simple moving average of $0.48 and a 200 day simple moving average of $1.41. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.